Across TCGA pan-cancer cohorts, PRELP mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PRELP data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PRELP mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRELP expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where PRELP mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	III,IV	0.227	0.781	.002	29	view →
PDAC	DFS	Median	II,III,IV	0.880	0.586	<.001	22	view →
LSCC	DFS	Median	II,III,IV	0.828	1.000	.003	15	view →
CCRCC	DFS	Median	III,IV	0.399	0.932	.022	12	view →
HNSC	DFS	Tertile	III,IV	0.872	0.638	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: PRELP tumor-vs-normal RNA expression · all PRELP data types